As of November 8, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Aclaris Therapeutics, Inc. The largest reported stake is BML Investment Partners, L.P.'s, at 9.9%. 14 filings are on record since July 17, 2025 (Schedule 13G/A, April 27, 2026).
Sell to companies like Aclaris Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Frazier Life Sciences Public Fund, L.P. · Sole voting: 0 · Shared voting: 7,879,943 · Sole dispositive: 0 · Shared dispositive: 7,879,943 · SCHEDULE 13G, 2026-09-21
- · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 12,723,026 · Sole dispositive: 0 · Shared dispositive: 12,723,026 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Vivo Opportunity Fund Holdings, L.P. · Percent: 4.3% · SCHEDULE 13G/A
- · Holder: BML Investment Partners, L.P. · Percent: 9.9% · SCHEDULE 13G/A
- · Holder: RA Capital Management, L.P. · Percent: 6.3% · SCHEDULE 13G
Aclaris Therapeutics, Inc. has 14 Schedule 13D or 13G filings on record since 2025-07-17. 6 holders' latest filing reports 5% or more of common stock, $0.00001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BML Investment Partners, L.P. | 9.9% | 13,950,000 | SCHEDULE 13G/A, 2026-04-27 | 2026-04-23 |
| Biosion, Inc. | 9.4% | 11,281,950 | SCHEDULE 13G/A, 2026-01-09 | 2025-12-09 |
| RA Capital Management, L.P. | 9.1% | 12,723,026 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Deep Track Capital, LP | 7% | 9,345,000 | SCHEDULE 13G, 2026-03-17 | 2026-03-09 |
| BlackRock, Inc. | 6.2% | 6,700,629 | SCHEDULE 13G/A, 2026-01-21 | 2025-12-31 |
| Frazier Life Sciences Public Fund, L.P. | 5.4% | 7,879,943 | SCHEDULE 13G, 2026-09-21 | 2026-09-14 |
| Adage Capital Management, L.P. | 4.87% | 5,278,144 | SCHEDULE 13G/A, 2025-11-13 | 2025-09-30 |
| Vivo Opportunity Fund Holdings, L.P. | 4.3% | 5,966,370 | SCHEDULE 13G/A, 2026-05-12 | 2026-03-31 |
| Millennium Management LLC | 3.5% | 3,837,380 | SCHEDULE 13G/A, 2025-07-24 | 2025-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind Aclaris Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Aclaris Therapeutics, Inc. and the records around it.
Aclaris Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- BML Investment Partners, L.P. also filed stake reports on 15 other companies: LENZ Therapeutics, Inc. (Nov 2026), Seer, Inc. (Nov 2026), Connect Biopharma Holdings Ltd (Oct 2026)
- Vivo Opportunity Fund Holdings, L.P. also filed stake reports on 20 other companies: ArriVent BioPharma, Inc. (Oct 2026), Clene Inc. (Aug 2026), Compass Therapeutics, Inc. (Aug 2026)
- Frazier Life Sciences Public Fund, L.P. also filed stake reports on 25 other companies: PHATHOM PHARMACEUTICALS, INC. (Nov 2026), Q32 Bio Inc. (Oct 2026), Allogene Therapeutics, Inc. (Aug 2026)
Watch Aclaris Therapeutics, Inc.
Get an email when Aclaris Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Aclaris Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Aclaris Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aclaris Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| RA Capital Management, L.P. | 0 | 12,723,026 | 0 | 12,723,026 | SCHEDULE 13G/A, 2026-08-14 |
| Peter Kolchinsky | 0 | 12,723,026 | 0 | 12,723,026 | SCHEDULE 13G/A, 2026-08-14 |
| Rajeev Shah | 0 | 12,723,026 | 0 | 12,723,026 | SCHEDULE 13G/A, 2026-08-14 |
| RA Capital Healthcare Fund, L.P. | 0 | 12,723,026 | 0 | 12,723,026 | SCHEDULE 13G/A, 2026-08-14 |
| Frazier Life Sciences Public Fund, L.P. | 0 | 7,879,943 | 0 | 7,879,943 | SCHEDULE 13G, 2026-09-21 |
| Fhmlsp, L.P. | 0 | 7,879,943 | 0 | 7,879,943 | SCHEDULE 13G, 2026-09-21 |
| Fhmlsp, L.L.C. | 0 | 7,879,943 | 0 | 7,879,943 | SCHEDULE 13G, 2026-09-21 |
| Frazier Life Sciences XI, L.P. | 0 | 86,910 | 0 | 86,910 | SCHEDULE 13G, 2026-09-21 |
| Fhmls Xi, L.P. | 0 | 86,910 | 0 | 86,910 | SCHEDULE 13G, 2026-09-21 |
| Fhmls Xi, L.L.C. | 0 | 86,910 | 0 | 86,910 | SCHEDULE 13G, 2026-09-21 |
| Frazier Life Sciences XII, L.P. | 0 | 762,663 | 0 | 762,663 | SCHEDULE 13G, 2026-09-21 |
| Fhmls Xii, L.P. | 0 | 762,663 | 0 | 762,663 | SCHEDULE 13G, 2026-09-21 |
| Fhmls Xii, L.L.C. | 0 | 762,663 | 0 | 762,663 | SCHEDULE 13G, 2026-09-21 |
The latest filing identifies Aclaris Therapeutics, Inc. by CUSIP 00461U105 and gives its principal executive office as 701 LEE ROAD, SUITE 103, WAYNE, PA 19087 (SCHEDULE 13G, 2026-09-21).
What the percentages are based on
Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.RA Capital Management, L.P., SCHEDULE 13G/A, 2026-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 5.1% | SCHEDULE 13G |
| 2025-07-24 | Millennium Management LLC | 3.5% | SCHEDULE 13G/A |
| 2025-07-29 | The Vanguard Group | 6.15% | SCHEDULE 13G |
| 2025-11-13 | Adage Capital Management, L.P. | 4.87% | SCHEDULE 13G/A |
| 2026-01-09 | Biosion, Inc. | 9.4% | SCHEDULE 13G/A |
| 2026-01-21 | BlackRock, Inc. | 6.2% | SCHEDULE 13G/A |
| 2026-02-09 | BML Investment Partners, L.P. | 11.9% | SCHEDULE 13G/A |
| 2026-03-17 | Deep Track Capital, LP | 7% | SCHEDULE 13G |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-07 | RA Capital Management, L.P. | 6.3% | SCHEDULE 13G |
| 2026-04-27 | BML Investment Partners, L.P. | 9.9% | SCHEDULE 13G/A |
| 2026-05-12 | Vivo Opportunity Fund Holdings, L.P. | 4.3% | SCHEDULE 13G/A |
| 2026-08-14 | RA Capital Management, L.P. | 9.1% | SCHEDULE 13G/A |
| 2026-09-21 | Frazier Life Sciences Public Fund, L.P. | 5.4% | SCHEDULE 13G |
Questions about who owns Aclaris Therapeutics, Inc.
Who owns Aclaris Therapeutics, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Aclaris Therapeutics, Inc.: BML Investment Partners, L.P. (9.9%, Schedule 13G/A, filed 2026-04-27), Biosion, Inc. (9.4%, Schedule 13G/A, filed 2026-01-09), RA Capital Management, L.P. (9.1%, Schedule 13G/A, filed 2026-08-14), Deep Track Capital, LP (7%, Schedule 13G, filed 2026-03-17) and BlackRock, Inc. (6.2%, Schedule 13G/A, filed 2026-01-21); 1 more is listed above.
Who are the largest shareholders of Aclaris Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Aclaris Therapeutics, Inc. on this page are BML Investment Partners, L.P. (9.9%), Biosion, Inc. (9.4%) and RA Capital Management, L.P. (9.1%).
When did BML Investment Partners, L.P. buy into Aclaris Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from BML Investment Partners, L.P. on this page is the Schedule 13G/A, filed 2026-02-09, reporting 11.9%; its latest, Schedule 13G/A filed 2026-04-27, reports 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 14 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Aclaris Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| December 4, 2024 | Form D, private offering | $80M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Aclaris Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.